Straits Times Index
3,348.48 +11.89 (+0.36%) Nikkei
38,962.42 +474.52 (+1.23%) Hang Seng
18,476.03 +396.42 (+2.19%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,780.47 +1,056.54 (+1.56%) CMC Crypto 200
1,482.33 +14.39 (+0.98%)
Eli Lilly and Co (LLY.HA)
| Previous close | 747.10 |
| Open | 755.00 |
| Bid | 758.30 x 0 |
| Ask | 759.90 x 0 |
| Day's range | 748.30 - 755.00 |
| 52-week range | 389.20 - 755.00 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
- PR Newswire
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
During the World Health Assembly today, Eli Lilly and Company (NYSE: LLY) announced it will donate $6.5 million to the United States Fund for UNICEF to expand UNICEF's work to improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India. This will bring the company's total commitment since 2022 to more than $20 million.
- PR Newswire
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, executive vice president, president of Lilly Diabetes and Obesity, and president of Lilly USA, will participate in a fireside chat at 4 p.m. Eastern time.
